Evolus, Inc. (NASDAQ:EOLS) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. lifted its stake in shares of Evolus, Inc. (NASDAQ:EOLS) by 0.7% during the fourth quarter, Holdings Channel reports. The firm owned 421,481 shares of the company’s stock after purchasing an additional 2,905 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in Evolus were worth $4,653,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of EOLS. China Universal Asset Management Co. Ltd. lifted its position in shares of Evolus by 10.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock valued at $148,000 after acquiring an additional 1,291 shares in the last quarter. Rhumbline Advisers grew its position in Evolus by 2.2% during the 4th quarter. Rhumbline Advisers now owns 80,149 shares of the company’s stock worth $885,000 after purchasing an additional 1,762 shares in the last quarter. Principal Financial Group Inc. raised its stake in Evolus by 9.8% during the 4th quarter. Principal Financial Group Inc. now owns 33,370 shares of the company’s stock valued at $368,000 after purchasing an additional 2,989 shares during the period. KBC Group NV purchased a new stake in shares of Evolus in the fourth quarter valued at $49,000. Finally, IFP Advisors Inc lifted its holdings in shares of Evolus by 17,440.7% in the fourth quarter. IFP Advisors Inc now owns 4,736 shares of the company’s stock valued at $52,000 after purchasing an additional 4,709 shares in the last quarter. 90.69% of the stock is owned by hedge funds and other institutional investors.

Evolus Trading Down 4.4 %

NASDAQ EOLS opened at $12.43 on Wednesday. The company has a market capitalization of $790.39 million, a PE ratio of -13.66 and a beta of 1.28. Evolus, Inc. has a 1-year low of $9.25 and a 1-year high of $17.82. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The firm’s fifty day simple moving average is $13.55 and its 200-day simple moving average is $13.84.

Insiders Place Their Bets

In other news, Director Karah Herdman Parschauer sold 12,888 shares of the stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $12.99, for a total transaction of $167,415.12. Following the transaction, the director now owns 32,183 shares in the company, valued at $418,057.17. This represents a 28.59 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Sandra Beaver sold 8,996 shares of the firm’s stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $119,286.96. Following the transaction, the chief financial officer now owns 173,583 shares in the company, valued at $2,301,710.58. This represents a 4.93 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 54,324 shares of company stock valued at $716,856 in the last three months. Insiders own 6.10% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on EOLS. HC Wainwright reiterated a “buy” rating and set a $27.00 price target on shares of Evolus in a report on Wednesday, March 5th. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Evolus in a report on Wednesday, March 5th. Finally, Barclays increased their price target on shares of Evolus from $22.00 to $25.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 5th.

Evolus Company Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.